News
Arthrosi drug trial in gout delivers for new owner Sobi
Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad.
Sunday 30 August 2026
